ES2806500T3 - Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas - Google Patents

Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas Download PDF

Info

Publication number
ES2806500T3
ES2806500T3 ES16740686T ES16740686T ES2806500T3 ES 2806500 T3 ES2806500 T3 ES 2806500T3 ES 16740686 T ES16740686 T ES 16740686T ES 16740686 T ES16740686 T ES 16740686T ES 2806500 T3 ES2806500 T3 ES 2806500T3
Authority
ES
Spain
Prior art keywords
seq
antibody
binding
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16740686T
Other languages
English (en)
Spanish (es)
Inventor
Beatrice Tien-Yi Wang
Max Allen Schwarzer
Bruce Alan Keyt
Ramesh Baliga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGM Biosciences Inc
Original Assignee
IGM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGM Biosciences Inc filed Critical IGM Biosciences Inc
Application granted granted Critical
Publication of ES2806500T3 publication Critical patent/ES2806500T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16740686T 2015-01-20 2016-01-20 Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas Active ES2806500T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105323P 2015-01-20 2015-01-20
PCT/US2016/014153 WO2016118641A1 (en) 2015-01-20 2016-01-20 Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
ES2806500T3 true ES2806500T3 (es) 2021-02-17

Family

ID=56417700

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16740686T Active ES2806500T3 (es) 2015-01-20 2016-01-20 Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas

Country Status (17)

Country Link
US (4) US10689449B2 (enExample)
EP (2) EP3750918A1 (enExample)
JP (4) JP7179464B2 (enExample)
KR (1) KR102435324B1 (enExample)
CN (1) CN107207601A (enExample)
AU (2) AU2016209324B2 (enExample)
CA (1) CA2972990A1 (enExample)
DK (1) DK3247728T3 (enExample)
ES (1) ES2806500T3 (enExample)
HU (1) HUE051013T2 (enExample)
IL (3) IL284430B2 (enExample)
NZ (1) NZ732922A (enExample)
PL (1) PL3247728T3 (enExample)
PT (1) PT3247728T (enExample)
SG (2) SG11201705116SA (enExample)
SI (1) SI3247728T1 (enExample)
WO (1) WO2016118641A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2922830A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
AU2015213593B2 (en) 2014-02-10 2020-09-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
KR102380402B1 (ko) 2014-04-03 2022-03-31 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
EP3750918A1 (en) 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN115093479A (zh) 2015-03-04 2022-09-23 Igm生物科学股份有限公司 Cd20结合分子及其用途
JP6882184B2 (ja) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ｂ型肝炎ウイルス抗原結合分子およびその使用
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
DK3355913T3 (da) 2015-09-30 2024-12-02 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
PL3455257T3 (pl) 2016-05-09 2022-01-17 Igm Biosciences Inc. Przeciwciała anty-pd-l1
US20190330360A1 (en) * 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
CN109843916B (zh) * 2016-08-12 2023-10-31 詹森生物科技公司 具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法
EP3360898A1 (en) * 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
JP7370580B2 (ja) 2017-04-06 2023-10-30 ウニヴェルズィテート シュトゥットガルト 結合および生物活性を改善した腫瘍壊死因子受容体（ｔｎｆｒ）結合タンパク質複合体
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CN108251443A (zh) * 2018-01-23 2018-07-06 深圳市人民医院 一种tnfrsf10c重组质粒、制备方法及其应用
WO2019157772A1 (zh) * 2018-02-13 2019-08-22 和元生物技术（上海）股份有限公司 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途
US20200392239A1 (en) * 2018-02-26 2020-12-17 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
WO2019169314A1 (en) 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
KR20210083260A (ko) * 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
JP7616671B2 (ja) 2019-06-24 2025-01-17 ウニヴェルズィテート シュトゥットガルト 改善された安定性を有するｔｎｆｒ２アゴニスト
KR102821105B1 (ko) * 2019-08-02 2025-06-13 장쑤 심시어 파마슈티컬 컴퍼니 리미티드 항-tnfr2 항체 및 이의 용도
CN114269785A (zh) 2019-08-15 2022-04-01 Igm生物科学股份有限公司 免疫刺激性多聚体结合分子
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
WO2021202863A1 (en) * 2020-04-02 2021-10-07 Promab Biotechnologies, Inc. Human ror-1 antibody and anti-ror-1-car-t cells
US20230212293A1 (en) 2020-04-22 2023-07-06 Igm Biosciences, Inc. Pd-1 agonist multimeric binding molecules
MX2022014259A (es) * 2020-05-12 2022-12-07 Igm Biosciences Inc Uso de una molecula de union anti-dr5 multimerica en combinacion con una terapia contra el cancer para tratar el cancer.
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
JP7203870B2 (ja) 2021-01-18 2023-01-13 イビデン株式会社 組電池用熱伝達抑制シート及び組電池
EP4314046A4 (en) * 2021-04-01 2025-03-19 ModernaTX, Inc. Mucosal expression of antibody structures and isotypes by mRNA
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
GB9015908D0 (en) 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
EP0642585B1 (en) 1992-05-18 2005-12-28 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
DE69427928T3 (de) 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
CA2139385C (en) 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
DK0809510T3 (da) 1995-01-26 2004-10-04 Biogen Inc Lymphotoxin-alfa/beta-komplekser og antilymphotoxin-beta-receptorantistoffer som antitumormidler
IL116784A (en) 1996-01-16 2000-01-31 Hadasit Med Res Service Device for examining viscoelasticity of a living or artificial tissue
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20060269558A1 (en) 1998-04-27 2006-11-30 Murphy Gerald P Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
SK288176B6 (sk) 1999-01-07 2014-04-02 Zymogenetics, Inc. Farmaceutický prostriedok obsahujúci fúzny proteín, izolovaná molekula polynukleotidu, expresný vektor, kultivovaná bunka, spôsob prípravy polypeptidu a izolovaný polypeptid
EP1159286A4 (en) 1999-03-04 2003-01-15 Human Genome Sciences Inc TUMOR NECROSIS FACTOR RECEPTORS 6 ALPHA AND 6 BETA
AU3623700A (en) 1999-03-11 2000-09-28 Reinhard Ebner Apoptosis inducing molecule ii and methods of use
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US7262005B1 (en) 2000-02-04 2007-08-28 Aurora Biosciences Corporation Methods of protein destabilization and uses thereof
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7094875B2 (en) 2000-06-23 2006-08-22 Maxygen, Inc. Co-stimulatory polypeptides
AU2001277531A1 (en) 2000-07-10 2002-01-21 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US6955717B2 (en) 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
US7115717B2 (en) 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
WO2002097046A2 (en) 2001-05-25 2002-12-05 Amgen, Inc. B7 related protein-2 molecules and uses thereof
US20050214210A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
CA2450129A1 (en) 2001-06-14 2002-12-27 Donald G. Jackson Novel human histone deacetylases
AU2002361784A1 (en) 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
GB0220205D0 (en) 2002-08-30 2002-10-09 Chiron Spa Neisseria toxin
BR0316737A (pt) 2002-11-27 2005-12-13 Irm Llc Métodos e composições para induzir apoptose em células cancerosas
WO2004069864A1 (fr) 2003-01-07 2004-08-19 Biomerieux Polypeptides f’ du virus de l’hepatite c, epitopes et leurs applications diagnostiques et therapeutiques
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
WO2005011720A1 (en) 2003-08-01 2005-02-10 Enhan Technology Holdings International Co., Ltd. Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury and proliferation and/or differentiation of neural stem cells in injured spinal cord
CN100427505C (zh) 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途
WO2006052641A2 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
WO2006063067A2 (en) 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
EP2431382A1 (en) 2005-01-21 2012-03-21 Epitopix, LLC Yersinia SPP, polypeptides and methods of use
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060269556A1 (en) 2005-04-18 2006-11-30 Karl Nocka Mast cell activation using siglec 6 antibodies
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
US20060269567A1 (en) 2005-05-16 2006-11-30 Liu Yuen Universal detoxifying composition
US20060269569A1 (en) 2005-05-16 2006-11-30 Liu Yuen Universal antioncotic and pain relieving ointment
AU2006249992B2 (en) 2005-05-24 2010-09-02 The United States Of America As Represented By The Secretary Of The Navy Anti-adhesin based passive immunoprophylactic
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
EP2287196A3 (en) 2006-01-13 2011-05-04 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
CN101074261A (zh) 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
EP2021500B1 (en) 2006-05-19 2014-12-31 Children, Youth and Women's Health Service Selective modulation of receptor signalling
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
KR100847010B1 (ko) 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
KR101544108B1 (ko) 2006-09-08 2015-08-13 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
NZ576445A (en) 2006-11-02 2012-03-30 Daniel J Capon Hybrid immunoglobulins with moving parts
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2219458B1 (en) 2007-11-08 2015-07-15 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
JP4560822B2 (ja) 2008-08-01 2010-10-13 Ａｘｉｓ株式会社 変形性関節症治療剤又は予防剤
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
CN102958537B (zh) 2010-04-07 2015-09-16 Abbvie公司 TNF-α结合蛋白
CN103221428B (zh) 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
WO2012057288A1 (ja) 2010-10-29 2012-05-03 第一三共株式会社 新規抗ｄｒ５抗体
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
AR086360A1 (es) 2011-04-21 2013-12-11 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
CA2849765C (en) 2011-09-26 2021-10-19 Jn Biosciences Llc Hybrid constant regions
US9382319B2 (en) * 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
MX2014004980A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17.
CA2863714C (en) 2012-02-08 2022-07-05 Igm Biosciences, Inc. Cdim binding proteins and uses thereof
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
EP2879719B1 (en) * 2012-08-01 2018-07-04 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
WO2014022592A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
US9725517B2 (en) 2012-10-26 2017-08-08 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences Humanized monoclonal antibodies against the extracellular domain of human death receptor 5
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
KR20160005345A (ko) 2013-05-07 2016-01-14 에프. 호프만-라 로슈 아게 삼량체성 항원 결합 분자
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
CA2922830A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
NZ720353A (en) 2013-12-30 2019-12-20 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
CA2936877C (en) 2014-01-16 2023-03-28 Mario Umberto Francesco MONDELLI Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
AU2015213593B2 (en) 2014-02-10 2020-09-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
EP3122779B1 (en) 2014-03-24 2019-05-22 Cancer Research Technology Limited Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
KR102380402B1 (ko) 2014-04-03 2022-03-31 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
KR20170063946A (ko) 2014-10-08 2017-06-08 에프. 호프만-라 로슈 아게 Fap 및 dr5에 특이적인 이중특이성 항체와 화학요법제의 병용요법
EP3750918A1 (en) 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
AU2015380455A1 (en) 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
CN115093479A (zh) 2015-03-04 2022-09-23 Igm生物科学股份有限公司 Cd20结合分子及其用途
JP6882184B2 (ja) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ｂ型肝炎ウイルス抗原結合分子およびその使用
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
EA201890171A1 (ru) 2015-06-30 2018-08-31 Сэнфорд-Бернхем Медикал Рисерч Инститьют Слитые белки btla агонисты и их применение
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
DK3355913T3 (da) 2015-09-30 2024-12-02 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
PL3455257T3 (pl) 2016-05-09 2022-01-17 Igm Biosciences Inc. Przeciwciała anty-pd-l1
US20190338040A1 (en) 2016-07-20 2019-11-07 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
US20190330374A1 (en) 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
US20190330360A1 (en) 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
CN109983033B (zh) 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
US20200392239A1 (en) 2018-02-26 2020-12-17 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
WO2019169314A1 (en) 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
KR20210083260A (ko) 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
CN114269785A (zh) 2019-08-15 2022-04-01 Igm生物科学股份有限公司 免疫刺激性多聚体结合分子
KR20220045030A (ko) 2019-08-17 2022-04-12 아이쥐엠 바이오사이언스 인코포레이티드 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도
BR112022003282A2 (pt) 2019-08-23 2022-05-24 Igm Biosciences Inc Glicovariantes de igm
AU2020351205A1 (en) 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
BR112022013071A2 (pt) 2020-01-06 2022-09-20 Igm Biosciences Inc Moléculas de ligação multiméricas altamente sialiladas
US20230212293A1 (en) 2020-04-22 2023-07-06 Igm Biosciences, Inc. Pd-1 agonist multimeric binding molecules
MX2022014259A (es) 2020-05-12 2022-12-07 Igm Biosciences Inc Uso de una molecula de union anti-dr5 multimerica en combinacion con una terapia contra el cancer para tratar el cancer.
CA3187008A1 (en) 2020-07-27 2022-02-03 Paul R. Hinton Multimeric coronavirus binding molecules and uses thereof
US20240002526A1 (en) 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
WO2022177870A1 (en) 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
MX2023009615A (es) 2021-02-17 2023-08-24 Igm Biosciences Inc Moleculas de union anti-cd123 y usos de estas.

Also Published As

Publication number Publication date
JP2024113039A (ja) 2024-08-21
JP2018503401A (ja) 2018-02-08
SG10202001779UA (en) 2020-04-29
IL253054A0 (en) 2017-08-31
JP7499813B2 (ja) 2024-06-14
US20210047419A1 (en) 2021-02-18
HUE051013T2 (hu) 2021-01-28
JP2022177090A (ja) 2022-11-30
AU2016209324B2 (en) 2020-02-27
EP3247728A1 (en) 2017-11-29
IL284430A (en) 2021-07-29
US20170320955A1 (en) 2017-11-09
AU2016209324A1 (en) 2017-07-06
NZ758252A (en) 2024-11-29
NZ732922A (en) 2022-07-29
IL308212A (en) 2024-01-01
IL284430B1 (en) 2023-12-01
CN107207601A (zh) 2017-09-26
JP7179464B2 (ja) 2022-11-29
WO2016118641A1 (en) 2016-07-28
US20180009897A1 (en) 2018-01-11
PL3247728T3 (pl) 2020-11-16
EP3247728A4 (en) 2018-07-04
PT3247728T (pt) 2020-07-16
AU2020201323A1 (en) 2020-03-12
US20230203173A1 (en) 2023-06-29
SG11201705116SA (en) 2017-08-30
US11578131B2 (en) 2023-02-14
IL253054B (en) 2021-08-31
KR102435324B1 (ko) 2022-08-23
KR20170105077A (ko) 2017-09-18
IL284430B2 (en) 2024-04-01
US10689449B2 (en) 2020-06-23
JP2021006044A (ja) 2021-01-21
EP3750918A1 (en) 2020-12-16
DK3247728T3 (da) 2020-07-13
CA2972990A1 (en) 2016-07-28
EP3247728B1 (en) 2020-04-15
AU2020201323B2 (en) 2022-03-31
US9938347B2 (en) 2018-04-10
SI3247728T1 (sl) 2020-09-30

Similar Documents

Publication Publication Date Title
ES2806500T3 (es) Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas
ES2874558T3 (es) Moléculas de unión a CD20 y usos de las mismas
US20210388098A1 (en) Multimeric cd137/4-1bb binding molecules and uses thereof
ES2914177T3 (es) Anticuerpos anti-OX40 humanizados y usos de los mismos
US20220106399A1 (en) Multimeric cd40 binding molecules and uses thereof
US20190330374A1 (en) Multimeric ox40 binding molecules and uses thereof
WO2018017889A1 (en) Multimeric gitr binding molecules and uses thereof
HK40043005A (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348B (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348A1 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof